Black Diamond Therapeutics Funding: $194M Raised, Series C
Black Diamond Therapeutics is based in Cambridge. It has raised $194M in total funding. Latest round: Series C.
Black Diamond Therapeutics funding overview
Black Diamond Therapeutics is based in Cambridge. Black Diamond Therapeutics has raised $194M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series C announced in December 2019. The round record for Black Diamond Therapeutics runs through 2019; nothing later has been disclosed. Investors on record include Boxer Capital, Wellington Management Company, BVF Partners L.P., Deerfield Management, Janus Henderson Investors, Casdin Capital and 9 others. 15 distinct backers are named across the disclosed rounds.
Frequently asked about Black Diamond Therapeutics funding
How much has Black Diamond Therapeutics raised?
Black Diamond Therapeutics has raised $194M in total disclosed funding across the rounds on record.
Who has invested in Black Diamond Therapeutics?
Boxer Capital, Wellington Management Company, BVF Partners L.P., Deerfield Management, Janus Henderson Investors, Casdin Capital are named among the investors backing Black Diamond Therapeutics.
What was the latest Black Diamond Therapeutics funding round?
The most recent disclosed round is a Series C, announced in December 2019.
Where is Black Diamond Therapeutics based?
Black Diamond Therapeutics is based in Cambridge.
When did Black Diamond Therapeutics last raise?
The last disclosed Black Diamond Therapeutics round closed in December 2019 at Series C.
Black Diamond Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Cambridge below to benchmark round size and investor mix.
Companies related to Black Diamond Therapeutics (35)
